Action

Low-Density Cholesterol Subfractions: Not all LDL-C Particles are Created Equal

Medical conventions are challenged every day. Already in the new year, the effectiveness of cold medicine and the gold standard in breast cancer treatment have been challenged. Standards in cholesterol testing are the latest casualty of medical innovation. For years, cholesterol has been measured by a simple panel o...

Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures

EAST HANOVER, N.J.--(BUSINESS WIRE)--Jul 11, 2007 - Since the May2007 release of a New England Journal of Medicine (NEJM) reportthat Avandia users are 43 percent more likely to suffer a heartattack and 67 percent more likely to die of cardiovascular causesthan non-users of Avandia, it is no surprise that physicians intendto switch many type 2 diabetes patients from Avandia to therapiesbelie...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1cReductions Observed in Phase 3 CARISA and MERLIN TIMI-36 ClinicalTrials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that researchers have completedpreliminary preclinical studies showing that ranolazine increasedglucose stimulated insulin secretion in pancreatic beta cells...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois

NEW YORK, June 22, 2007 /PRNewswire-FirstCall/ -- KeryxBiopharmaceuticals, Inc. today announced that abstracts related toSulonex(TM) (sulodexide oral gelcap) have been selected forpublication or presentation during the poster sessions scheduled totake place at the upcoming American Diabetes Association (ADA) 67thAnnual Scientific Sessions and exposition at the McCormick PlaceLakeside Cen...

Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -

DOYLESTOWN, Pa., June 20, 2007 /PRNewswire-FirstCall/ -- QuigleyPharma, <a target="_blank" href="http://www.quigleypharma.com/">www.QuigleyPharma.com , a whollyowned subsidiary of The Quigley Corporation announced today that ithas completed a follow-up study to evaluate the impact of QR-443 onlevels of a pro-inflammatory cytokine Interleukin-6 (IL-6) in acachexia model. This new data...

Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action

SALT LAKE CITY, June 14, 2007 /PRNewswire/ -- ProlexysPharmaceuticals and announced today a publication describing theproperties of the selective small molecule anti-tumor agent,erastin. Prolexys and Columbia applied the company'schemi-proteomics technology to understand the mechanism of actionof erastin. The results, to be published in the June 14, 2007 issueof the journal Nature reveal...

Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II Study

- Results Presented at the 12th Congress of European HematologyAssociation (EHA) - VIENNA, Austria, June 11, 2007 /PRNewswire-FirstCall/ --Immunomedics, Inc. , a biopharmaceutical company focused ondeveloping monoclonal antibodies to treat cancer and other seriousdiseases, today announced that data presented at the 12th Congressof EHA in Vienna, Austria, showed positive responses in patie...

Studies Presented at Neurology Conference Highlight Early Efficacy, Long-Term Tolerability, and High Patient Satisfaction with Betaseron

BOSTON, May 03, 2007 /PRNewswire/ -- Bayer HealthCarePharmaceuticals announced today the results of three clinicalstudies with Betaseron(R) (interferon beta-1b), presented this weekat the American Academy of Neurology's (AAN) 59th Annual Meeting,demonstrating early efficacy, long-term tolerability, and highpatient satisfaction with treatment in patients with relapsingforms of multiple sc...

New Report Illuminates Ampligen's Unique Mechanism of Action

PHILADELPHIA--(BUSINESS WIRE)--Apr 30, 2007 - Hemispherx Biopharma,Inc. (AMEX: HEB) announced today the first scientific publication(Journal of Immunology, April 2007) that explains the uniquetherapeutic properties of its proprietary experimental therapeutic,Ampligen(R) (Poly I : Poly C(12)U), a double-stranded RNA beingtested as a monotherapy for Chronic Fatigue Syndrome and as anadjuvant...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

Risk of Having a Venous ThromboEmbolism (VTE) is Reduced by aSignificant 43% in Acute Ischemic Stroke Patients Treated WithClexane(R) / Lovenox(R) BRIDGEWATER, N.J., April 20, 2007 /PRNewswire-FirstCall/ --Sanofi-aventis announced the publication of the PREVAIL (Preventionof VTE after Acute Ischemic Stroke with LMWH Enoxaparin) trial inthe April 21st issue of The Lancet. The results of th...

Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR

Myriad Genetics Presents Studies Characterizing Vascular DisruptionCapabilities of Azixa(TM) TARRYTOWN, N.Y., April 20, 2007 /PRNewswire-FirstCall/ --EpiCept Corporation reported today that studies characterizing adual mode of action for Azixa(TM), a compound licensed by theCompany to Myriad Genetics, Inc. for the treatment of primary andsecondary brain tumors, were presented at the annua...

Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

EXTON, Pa.--(BUSINESS WIRE)--Apr 19, 2007 - Othera Pharmaceuticals,Inc. today announced that Dr. Shaker Mousa, Professor ofPharmacology and Executive Vice President and Chairman of thePharmaceutical Research Institute at Albany College of Pharmacy,will present new preclinical data detailing the observedantithrombotic effect of Othera's lead compound, OT-551, andrelated Othera compounds. Thi...

Myriad Genetics Presents Azixa's Mode of Action at AACR

Azixa Shows Dual Activity as Vascular Disrupting Agent andTubulin Inhibitor SALT LAKE CITY, UT, April 17, 2007—Myriad Genetics, Inc.(NASDAQ: MYGN) (<a target="_blank" href="http://www.myriad.com/">www.myriad.com ) announced today thatit presented studies that characterize the mode of action of itsinvestigational new drug, Azixa™, as a vascular disruptingagent, at th...

GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy

GAITHERSBURG, Md.--(BUSINESS WIRE)--Apr 17, 2007 - GenVec, Inc.(Nasdaq:GNVC) announced today data from two studies presented atthe 97th annual meeting of the American Association of CancerResearch (AACR) that further support the use of adenovector systemsto deliver the gene for tumor necrosis factor-alpha (TNF(alpha)).GenVec's lead product candidate, TNFerade(TM) biologic (TNFerade)is an ad...

Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells

NEW YORK--(BUSINESS WIRE)--Apr 16, 2007 - Arsenic, a naturallyoccurring element, has been used in therapeutic compounds for over2,000 years, and even now remains a venerable constituent of thetraditional Chinese pharmacopeia. Today, due in measure to the efforts of investigators supportedby grants from the Samuel Waxman Cancer Research Foundation's(SWCRF) "Institute Without Walls," an ars...

DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy

EVRY, France, April 12, 2007 /PRNewswire/ -- DNA TherapeuticsS.A. an emerging pharmaceutical company specialized in innovativecancer therapy announces today the elucidation of a new mechanismof action and the identification of a biomarker of itsfirst-in-class antitumoral lead molecule Dbait. It will bepresented at the forecoming American Association for CancerResearch annual meeting 2007...